These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8993382)

  • 1. Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria.
    Tzianabos AO; Cisneros RL
    Ann N Y Acad Sci; 1996 Oct; 797():285-7. PubMed ID: 8993382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity.
    Liang J; Melican D; Cafro L; Palace G; Fisette L; Armstrong R; Patchen ML
    Int J Immunopharmacol; 1998 Nov; 20(11):595-614. PubMed ID: 9848393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic anti-infective activity of poly-[1-6]-beta-D-glucopyranosyl-[1-3]-beta-D-glucopryanose glucan in a guinea pig model of staphylococcal wound infection.
    Kernodle DS; Gates H; Kaiser AB
    Antimicrob Agents Chemother; 1998 Mar; 42(3):545-9. PubMed ID: 9517930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients.
    Babineau TJ; Marcello P; Swails W; Kenler A; Bistrian B; Forse RA
    Ann Surg; 1994 Nov; 220(5):601-9. PubMed ID: 7979607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergism between poly-(1-6)-beta-D-glucopyranosyl-(1-3)-beta-D-glucopyranose glucan and cefazolin in prophylaxis of staphylococcal wound infection in a guinea pig model.
    Kaiser AB; Kernodle DS
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2449-51. PubMed ID: 9736583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor.
    Wakshull E; Brunke-Reese D; Lindermuth J; Fisette L; Nathans RS; Crowley JJ; Tufts JC; Zimmerman J; Mackin W; Adams DS
    Immunopharmacology; 1999 Feb; 41(2):89-107. PubMed ID: 10102791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
    Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
    Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive transfer of poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose glucan protection against lethal infection in an animal model of intra-abdominal sepsis.
    Cisneros RL; Gibson FC; Tzianabos AO
    Infect Immun; 1996 Jun; 64(6):2201-5. PubMed ID: 8675327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthrax-protective effects of yeast beta 1,3 glucans.
    Kournikakis B; Mandeville R; Brousseau P; Ostroff G
    MedGenMed; 2003 Mar; 5(1):1. PubMed ID: 12827062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against experimental intraabdominal sepsis by two polysaccharide immunomodulators.
    Tzianabos AO; Gibson FC; Cisneros RL; Kasper DL
    J Infect Dis; 1998 Jul; 178(1):200-6. PubMed ID: 9652441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PGG-Glucan activates NF-kappaB-like and NF-IL-6-like transcription factor complexes in a murine monocytic cell line.
    Adams DS; Pero SC; Petro JB; Nathans R; Mackin WM; Wakshull E
    J Leukoc Biol; 1997 Dec; 62(6):865-73. PubMed ID: 9400829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced neutrophil emigration and Porphyromonas gingivalis reduction following PGG-glucan treatment of mice.
    Niederman R; Kelderman H; Socransky S; Ostroff G; Genco C; Kent R; Stashenko P
    Arch Oral Biol; 2002 Aug; 47(8):613-8. PubMed ID: 12221019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of rat macrophages by Betafectin PGG-glucan requires cross-linking of membrane receptors distinct from complement receptor three (CR3).
    Michalek M; Melican D; Brunke-Reese D; Langevin M; Lemerise K; Galbraith W; Patchen M; Mackin W
    J Leukoc Biol; 1998 Sep; 64(3):337-44. PubMed ID: 9738660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucan enhances survival in an intraabdominal infection model.
    Bowers GJ; Patchen ML; MacVittie TJ; Hirsch EF; Fink MP
    J Surg Res; 1989 Aug; 47(2):183-8. PubMed ID: 2755122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group.
    Dellinger EP; Babineau TJ; Bleicher P; Kaiser AB; Seibert GB; Postier RG; Vogel SB; Norman J; Kaufman D; Galandiuk S; Condon RE
    Arch Surg; 1999 Sep; 134(9):977-83. PubMed ID: 10487593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PGG-glucan, a leukocyte-specific immunostimulant, does not potentiate GVHD or allograft rejection.
    Washburn WK; Otsu I; Gottschalk R; Monaco AP
    J Surg Res; 1996 May; 62(2):179-83. PubMed ID: 8632636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel carbohydrate-glycosphingolipid interaction between a beta-(1-3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes.
    Zimmerman JW; Lindermuth J; Fish PA; Palace GP; Stevenson TT; DeMong DE
    J Biol Chem; 1998 Aug; 273(34):22014-20. PubMed ID: 9705343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients.
    Babineau TJ; Hackford A; Kenler A; Bistrian B; Forse RA; Fairchild PG; Heard S; Keroack M; Caushaj P; Benotti P
    Arch Surg; 1994 Nov; 129(11):1204-10. PubMed ID: 7979954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of experimental gram-negative and gram-positive bacterial sepsis with the hematoregulatory peptide SK&F 107647.
    DeMarsh PL; Wells GI; Lewandowski TF; Frey CL; Bhatnagar PK; Ostovic EJ
    J Infect Dis; 1996 Jan; 173(1):203-11. PubMed ID: 8537660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan.
    Patchen ML; Vaudrain T; Correira H; Martin T; Reese D
    Exp Hematol; 1998 Dec; 26(13):1247-54. PubMed ID: 9845381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.